Skin Webinar Series, Part 3: What you should know about skin cancer treatment
According to the Skin Cancer Foundation, skin cancer is the most prevalent cancer type in the US. Roughly 20% of Americans will develop skin cancer before the age of 70. Despite these facts:
- 72% of Americans do not know that non-melanoma skin cancers can metastasize, or spread, and become life-threatening.
- Over half of those living in the US think melanoma is the most common skin cancer.
This is part 3 in a 3-part series that will help empower you with knowledge about skin cancer.
This video will help you:
- Understand the different treatment options
- Learn about radiation therapy for skin cancer
- Consider GenesisCare as an option for your treatment needs
Dr. Sura is a Radiation Oncologist practicing at our Bonita Springs and Naples locations (733 4th Avenue, 1885 SW Health Parkway and 8350 Sierra Meadows).
She earned her medical degree at George Washington University School of Medicine and Health Sciences in Washington D.C., followed by a research fellowship at Memorial Sloan Kettering in New York City, and a residency in radiation oncology at SUNY Downstate Medical Center in Brooklyn. Additionally, she earned a Master’s in Business Administration through the New York University Stern Executive MBA Program. She is board certified in Radiation Oncology from the American Board of Radiology.
About skin cancer treatment at GenesisCare
Skin cancer is the most common cancer diagnosed in the United States. At GenesisCare, we use the latest radiation therapy techniques to treat skin cancer, without the use of surgery or general anesthetic.
About Sonal Sura, MD
Sonal Sura, MD, MBA has a special interest in breast, skin and GI malignancies. She is Board Certified with the American Board of Radiology in the specialty of Radiation Oncology. Before relocating to Naples, FL to join GenesisCare Oncology, she served as the Director of Radiation Oncology at NYC H+H/Elmhurst, NY and Assistant Professor at the Icahn School of Medicine at Mount Sinai.